HOMEPRODUCTSCOMPANYCONTACTFAQResearchDictionaryPharmaSign Up FREE or Login

A Role for Adrenergic Receptors in the Uterotonic Effects of Ergometrine in Isolated Human Term Nonlaboring Myometrium.

AbstractBACKGROUND:
Ergometrine is a uterotonic agent that is recommended in the prevention and management of postpartum hemorrhage. Despite its long-standing use, the mechanism by which it acts in humans has never been elucidated fully. The objective of this study was to investigate the role of adrenoreceptors in ergometrine's mechanism of action in human myometrium. The study examined the hypothesis that α-adrenoreceptor antagonism would result in the reversal of the uterotonic effects of ergometrine.
METHODS:
Myometrial samples were obtained from women undergoing elective cesarean delivery. The samples were then dissected into strips and mounted in organ bath chambers. After the generation of an ergometrine concentration-response curve (10 to 10 M), strips were treated with increasing concentrations of ergometrine (10 to 10 M) alone and ergometrine (10 to 10 M) in the presence of phentolamine (10 M), prazosin (10 M), propranolol (10 M), or yohimbine (10 M). The effects of adding ergometrine and the effect of drug combinations were analyzed using linear mixed effects models with measures of amplitude (g), frequency (contractions/10 min), and motility index (g×contractions/10 min).
RESULTS:
A total of 157 experiments were completed on samples obtained from 33 women. There was a significant increase in the motility index (adding 0.342 g × counts/10 min/μM; 95% confidence interval [CI], 0.253-0.431, P < .001), amplitude (0.078 g/μM; 95% CI, 0.0344-0.121, P = 5e-04), and frequency (0.051 counts/10 min/μM; 95% CI, 0.038-0.063, P < .001) in the presence of ergometrine. The α-adrenergic antagonist phentolamine and the more selective α1-adrenergic antagonist prazosin inhibited the ergometrine mediated increase in motility index, amplitude, and frequency (-1.63 g × counts/10 min/μM and -16.70 g × counts/10 min/μM for motility index, respectively).
CONCLUSIONS:
These results provide novel evidence for a role for α-adrenergic signaling mechanisms in the action of ergometrine on human myometrial smooth muscle in the in vitro setting. Information that sheds light on the mechanism of action of ergometrine may have implications for the development of further uterotonic agents.
AuthorsRebecca A Fanning, Florike Sheehan, Claire Leyden, Niamh Duffy, Luis F Iglesias-Martinez, Michael F Carey, Deirdre P Campion, John J O'Connor
JournalAnesthesia and analgesia (Anesth Analg) Vol. 124 Issue 5 Pg. 1581-1588 (05 2017) ISSN: 1526-7598 [Electronic] United States
PMID28207596 (Publication Type: Journal Article, Research Support, Non-U.S. Gov't)
Chemical References
  • Adrenergic alpha-Antagonists
  • Adrenergic beta-Antagonists
  • Oxytocics
  • Receptors, Adrenergic, alpha
  • Ergonovine
Topics
  • Adrenergic alpha-Antagonists (pharmacology)
  • Adrenergic beta-Antagonists (pharmacology)
  • Adult
  • Cesarean Section
  • Dose-Response Relationship, Drug
  • Drug Interactions
  • Ergonovine (pharmacology)
  • Female
  • Humans
  • In Vitro Techniques
  • Myometrium (drug effects)
  • Oxytocics (pharmacology)
  • Pregnancy
  • Receptors, Adrenergic, alpha (drug effects)
  • Uterine Contraction (drug effects)
  • Uterus (drug effects)

Join CureHunter, for free Research Interface BASIC access!

Take advantage of free CureHunter research engine access to explore the best drug and treatment options for any disease. Find out why thousands of doctors, pharma researchers and patient activists around the world use CureHunter every day.
Realize the full power of the drug-disease research graph!


Choose Username:
Email:
Password:
Verify Password:
Enter Code Shown: